11 results on '"Zhang, Xuewu"'
Search Results
2. Long noncoding RNA SNHG14 promotes hepatocellular carcinoma progression by regulating miR-876-5p/SSR2 axis
- Author
-
Liao, Zhibin, Zhang, Hongwei, Su, Chen, Liu, Furong, Liu, Yachong, Song, Jia, Zhu, He, Fan, Yawei, Zhang, Xuewu, Dong, Wei, Chen, Xiaoping, Liang, Huifang, and Zhang, Bixiang
- Published
- 2021
- Full Text
- View/download PDF
3. 14–3-3ζ inhibits heme oxygenase-1 (HO-1) degradation and promotes hepatocellular carcinoma proliferation: involvement of STAT3 signaling
- Author
-
Song, Jia, Zhang, Xiaochao, Liao, Zhibin, Liang, Huifang, Chu, Liang, Dong, Wei, Zhang, Xuewu, Ge, Qianyun, Liu, Qiumeng, Fan, Pan, Zhang, Zhanguo, and Zhang, Bixiang
- Published
- 2019
- Full Text
- View/download PDF
4. Anticancer potential of Bacillus coagulans MZY531 on mouse H22 hepatocellular carcinoma cells via anti-proliferation and apoptosis induction.
- Author
-
Zhao, Zhongwei, Yang, Qian, Zhou, Tingting, Liu, Chunhong, Sun, Manqing, Cui, Xinmu, and Zhang, Xuewu
- Subjects
THERAPEUTIC use of antineoplastic agents ,BIOLOGICAL models ,FLOW cytometry ,LIVER tumors ,STAINS & staining (Microscopy) ,WESTERN immunoblotting ,ONE-way analysis of variance ,MULTIVARIATE analysis ,ANIMAL experimentation ,BACILLUS (Bacteria) ,APOPTOSIS ,CELL physiology ,CELLULAR signal transduction ,GENE expression ,CELL survival ,CELL proliferation ,TRANSFERASES ,DESCRIPTIVE statistics ,RESEARCH funding ,DATA analysis software ,HEPATOCELLULAR carcinoma ,MICE ,CASPASES - Abstract
Bacillus coagulans have recently revealed its anticancer effects, but few investigations are available on their effects on liver cancer proliferation, and the precise mechanism to mark its impact on apoptosis-related signaling pathways has yet to be elucidated. The aim of this study was to evaluate the anti-proliferative effect of B. coagulans MZY531 and apoptosis induction in the mouse H22 hepatocellular carcinoma cell line. The anti-proliferative activity of B. coagulans MZY531 was evaluated by Cell Counting Kit-8 (CCK-8) assay, and cell apoptosis was revealed with Terminal Deoxynucleotidyl Transferase (TDT)-mediated dUTP Nick-End Labeling (TUNEL) staining and flow cytometric analysis. The expressions of apoptosis-related protein were determined by western blot analysis. The CCK-8 assay revealed that B. coagulans MZY531 inhibited the H22 cells proliferation in a concentration-dependent manner. TUNEL staining revealed an increased apoptosis rate in H22 cells following intervention with B. coagulans MZY531. Furthermore, flow cytometric analysis showed that B. coagulans MZY531 treatment (MOI = 50 and 100) significantly alleviated the H22 cells apoptosis compared with the control group. Western blot analysis found B. coagulans MZY531 significantly decreased level of phospho-PI3K (p-PI3K), phospho-AKT (p-AKT), and phospho-mTOR (p-mTOR) compared with the control group. Furthermore, H22 cells treatment with B. coagulans MZY531 enhanced the expression of caspase-3 and Bax and jeopardized the expression of Bcl-2. Taken together, apoptosis induction and cell proliferation inhibition via PI3K/AKT/mTOR and Bax/Bcl-2/Caspase-3 pathway are promising evidence to support B. coagulans MZY531 as a potential therapeutic agent for cancer. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
5. Ginsenoside compound K induces mitochondrial apoptosis in human hepatoma cells through Bclaf1-mediated modulation of ERK signaling.
- Author
-
Chen, Jiaxin, Sun, Manqing, Cui, Xinmu, and Zhang, Xuewu
- Subjects
GINSENOSIDES ,MITOCHONDRIA ,HEPATOCELLULAR carcinoma ,APOPTOSIS ,TRANSCRIPTION factors ,CELL proliferation - Abstract
Compound K (CK) is the metabolite and final active ingredient of diol-type ginsenosides. In this study, we investigated the effect of CK on mitochondrial apoptosis in SMMC-7721 and BEL-7404 cells and the regulatory mechanism through in vitro and in vivo experiments. The results demonstrated that CK inhibited Hepatocellular carcinoma (HCC) cells proliferation and arrested the cells in G0/G1 phase. CK induces mitochondrial apoptosis in HCC cells and inhibited p-ERK expression. Bcl-2 associated transcription factor 1 (Bclaf1) was distributed in the nucleus and cytoplasm, and CK inhibited its expression. Treatment of a nude mouse xenograft model bearing SMMC-7721 cells with CK decreased the expression of Bclaf1, p-ERK, and Bcl-2 but increased that of Bax. In summary, ginsenoside CK downregulated Bclaf1 expression, inhibited the activation of the ERK pathway, and triggered mitochondrial apoptosis in HCC. These findings uncovered a potential therapeutic strategy leveraging the anti-tumor effects of CK against HCC. [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF
6. Curcumin inhibits invasion and metastasis of human hepatoma cells through Bclaf1-mediated Wnt/β-catenin signalling.
- Author
-
Zhao, Zhongwei, Su, Jielin, Zhao, Jiaqi, Chen, Jiaxin, Cui, Xinmu, Sun, Manqing, and Zhang, Xuewu
- Subjects
CURCUMIN ,WNT signal transduction ,HEPATOCELLULAR carcinoma ,METASTASIS ,INTRAPERITONEAL injections ,CELLULAR signal transduction ,GENE targeting - Abstract
Curcumin, a kind of natural compound extracted from the rhizome of Zingiberaceae such as turmeric, has many pharmacological effects such as anti-cancer effects. This study investigated the effect of curcumin on the invasion and metastasis of hepatocellular carcinoma (HCC) cell lines HepG2 and SK-Hep-1 through the Wnt/β-catenin signalling pathway and the regulatory mechanism of Bcl-2-associated transcription factor 1 (Bclaf1). Curcumin significantly inhibited the migration and invasion of HepG2 and SK-Hep-1 cells and inhibited the Wnt/β-catenin signalling pathway and reduced Bclaf1 expression in human hepatoma cells. In nude mice, intraperitoneal injection of curcumin significantly inhibited the growth of subcutaneously transplanted tumours and reduced lung metastasis of the tumour cells, downregulated the expression of Bclaf1, and inhibited the Wnt/β-catenin pathway. This study suggests that curcumin is a novel candidate drug to prevent cancer metastasis and that Bclaf1 is a new gene target related to the proliferation, invasion, and metastasis of hepatocellular carcinoma. [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF
7. GP73 represses host innate immune response to promote virus replication by facilitating MAVS and TRAF6 degradation.
- Author
-
Zhang, Xuewu, Zhu, Chengliang, Wang, Tianci, Jiang, Hui, Ren, Yahui, Zhang, Qi, Wu, Kailang, Liu, Fang, Liu, Yingle, and Wu, Jianguo
- Subjects
- *
PHYSIOLOGICAL effects of proteins , *IMMUNE response , *VIRAL replication , *HEPATITIS C , *PROTEIN expression - Abstract
Hepatitis C virus (HCV) infection is a leading cause of chronic liver diseases and hepatocellular carcinoma (HCC) and Golgi protein 73 (GP73) is a serum biomarker for liver diseases and HCC. However, the mechanism underlying GP73 regulates HCV infection is largely unknown. Here, we revealed that GP73 acts as a novel negative regulator of host innate immunity to facilitate HCV infection. GP73 expression is activated and correlated with interferon-beta (IFN-β) production during HCV infection in patients’ serum, primary human hepatocytes (PHHs) and human hepatoma cells through mitochondrial antiviral signaling protein (MAVS), TNF receptor-associated factor 6 (TRAF6) and mitogen-activated protein kinase kinase/extracellular regulated protein kinase (MEK/ERK) pathway. Detailed studies revealed that HCV infection activates MAVS that in turn recruits TRAF6 via TRAF-interacting-motifs (TIMs), and TRAF6 subsequently directly recruits GP73 to MAVS via coiled-coil domain. After binding with MAVS and TRAF6, GP73 promotes MAVS and TRAF6 degradation through proteasome-dependent pathway. Moreover, GP73 attenuates IFN-β promoter, IFN-stimulated response element (ISRE) and nuclear factor κB (NF-κB) promoter and down-regulates IFN-β, IFN-λ1, interleukin-6 (IL-6) and IFN-stimulated gene 56 (ISG56), leading to the repression of host innate immunity. Finally, knock-down of GP73 down-regulates HCV infection and replication in Huh7-MAVSR cells and primary human hepatocytes (PHHs), but such repression is rescued by GP73m4 (a mutant GP73 resists to GP73-shRNA#4) in Huh7-MAVSR cells, suggesting that GP73 facilitates HCV infection. Taken together, we demonstrated that GP73 acts as a negative regulator of innate immunity to facilitate HCV infection by interacting with MAVS/TRAF6 and promoting MAVS/TRAF6 degradation. This study provides new insights into the mechanism of HCV infection and pathogenesis, and suggests that GP73 is a new potential antiviral target in the prevention and treatment of HCV associated diseases. [ABSTRACT FROM AUTHOR]
- Published
- 2017
- Full Text
- View/download PDF
8. Golgi protein 73 facilitates the interaction of hepatitis C virus NS5A with apolipoprotein E to promote viral particle secretion.
- Author
-
Zhang, Xuewu, Wang, Tianci, Dai, Xuechen, Zhang, Yecheng, Jiang, Hui, Zhang, Qi, Liu, Fang, Wu, Kailang, Liu, Yingle, Zhou, Hong, and Wu, Jianguo
- Subjects
- *
MEMBRANE proteins , *HEPATITIS C diagnosis , *APOLIPOPROTEIN E , *BIOMARKERS , *GENE expression - Abstract
Hepatitis C virus (HCV) infection is one of the leading causes of chronic liver diseases and hepatocellular carcinoma (HCC). Golgi protein 73 (GP73), a resident Golgi membrane protein, is a novel serum biomarker for the diagnosis of liver diseases and HCC. Although previous studies have demonstrated that HCV upregulates GP73 expression and GP73 promotes HCV secretion through its interaction with apolipoprotein E (ApoE), the exact mechanism underlying GP73 regulates HCV secretion remains unclear. In this study, we demonstrated that GP73 mediates the interaction of ApoE with HCV NS5A protein to promote HCV secretion. We revealed that GP73 is colocalized with HCV replication complex in infected-Huh7.5.1 cells. Further studies demonstrated that GP73 interacted with both NS5A and ApoE proteins. Furthermore, knockdown of GP73 significantly reduced the binding of NS5A with ApoE, and the production of virus particles in culture supernatant. Taken together, our studies revealed that GP73 promotes HCV secretion by directly mediating the interaction of ApoE with HCV replication complex through binding with HCV NS5A. [ABSTRACT FROM AUTHOR]
- Published
- 2016
- Full Text
- View/download PDF
9. Based on network pharmacology and experiments to explore the underlying mechanism of Mahonia bealei (Fortune) Carrière for treating alcoholic hepatocellular carcinoma.
- Author
-
Zhang, Nannan, Zhu, Yi, Zhang, Xuewu, Yang, Kaiping, Yang, Xia, An, Mingyu, Tian, Changlin, and Li, Jun
- Subjects
- *
MEDICINAL plants , *RANDOM forest algorithms , *BIOINFORMATICS , *PLANT extracts , *PHARMACEUTICAL chemistry , *RECEIVER operating characteristic curves , *HEPATOCELLULAR carcinoma , *PROPORTIONAL hazards models - Abstract
Mahonia bealei (Fortune) Carrière (M. bealei) is a traditional medicine widely used by the Hmong community in Guizhou. It possesses diverse biological activities and shows promise in cancer treatment; however, contemporary pharmacological research in this area is lacking. This study aimed to investigate the effects and underlying mechanisms of M. bealei on alcoholic hepatocellular carcinoma (HCC). We initially employed the LC-MS/MS method to identify the compounds present in M. bealei serum. Subsequently, its potential targets were predicted using public databases. Bioinformatics and network pharmacology approaches, such as univariate Cox regression and random forest (RF) algorithms, were utilized to identify differentially expressed genes (DEGs) associated with the prognosis of alcoholic HCC. Survival curve and receiver operating characteristic (ROC) analyses were conducted using alcoholic HCC-related data from TCGA and GEO to determine the diagnostic value of the identified DEGs. Molecular docking using the CDOCKER approach based on CHARMm was performed to validate the affinity between the predictive compounds and targets. Additionally, we evaluated the impact of M. bealei on cell proliferation, migration, and conducted western blot assays. The LC-MS/MS approach identified 17 therapeutic components and predicted 483 component-related targets, of which 63 overlapped with alcoholic HCC targets and were considered potential therapeutic targets. GO and KEGG pathway analysis revealed significant associations between the 63 overlapping targets and alcoholic HCC progression. Through various approaches in the Cytoscape 3.9.0 software, we confirmed 9 hub genes (CDK1 , CXCR4 , DNMT1 , ESR1 , KIT , PDGFRB , SERPINE1 , TOP2A , and TYMS) as core targets. TOP2A and CDK1 genes were identified as advantageous for diagnosing alcoholic HCC using univariate Cox regression, RF, survival curve, and ROC analysis. Molecular docking analysis demonstrated strong binding affinity between key bioactive components cyclamic acid, perfluoroalkyl carboxylic acid, perfluorosulfonic acid, alpha-linolenic acid, adenosine receptor antagonist (CGS 15943), and Prodigiosin and TOP2A and CDK1. In vitro experiments confirmed that M. bealei significantly suppressed cell proliferation and migration of HepG2 cells, while downregulating TOP2A and CDK1 expression. This study highlights the potential of M. bealei as a natural medicine for the treatment of alcoholic HCC. Six compounds (cyclamic acid, perfluoroalkylic carboxylic acids, perfluorosulfonic acid, alpha-linolenic acid, adenosine receptor antagonist (CGS 15943), and Prodigiosin) present in M. bealei serum may exhibit therapeutic effects against alcoholic HCC by downregulating CDK1 and TOP2A expression levels in vitro. [Display omitted] [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
10. Inhibition of PTPRE suppresses tumor progression and improves sorafenib response in hepatocellular carcinoma.
- Author
-
Dong, Renshun, Wang, Tianci, Dong, Wei, Zhu, He, Liu, Qiumeng, Liang, Huifang, Chen, Xiaoping, Zhang, Bixiang, and Zhang, Xuewu
- Subjects
- *
CANCER invasiveness , *SORAFENIB , *PROTEIN-tyrosine phosphatase , *PHOSPHOPROTEIN phosphatases , *SMALL molecules , *ANIMAL models in research , *HEPATOCELLULAR carcinoma - Abstract
Hepatocellular carcinoma (HCC) has a poor prognosis, and the efficacy of current therapeutic strategies is extremely limited in advanced diseases. Our previous study reported that protein tyrosine phosphatase receptor epsilon (PTPRE) is a promoting factor in HCC progression. In this study, our objective was to evaluate the treatment effect of PTPRE inhibitors in different HCC preclinical models. Our results indicated that the PTPRE inhibitory compound 63 (Cpd-63) inhibited tumor cell proliferation, migration, and HCC organoid growth. Mechanism research revealed that Cpd-63 could inhibit the expression of MYC and MYC targets by inhibiting the activation of SRC. Additionally, we found that Cpd-63 could improve the response of sorafenib in HCC cells. In conclusion, we demonstrated that the PTPRE inhibitors represented a potential therapeutic agent for HCC management. [Display omitted] • Targeting PTPRE selectively by small molecule is novel strategy for HCC therapy. • The PTPRE inhibitor Cpd-63 suppresses HCC progression in preclinical models. • Cpd-63 suppresses the expression of MYC by inhibiting the activation of SRC. • PTPRE inhibitors improve the response of sorafenib in HCC cells. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
11. Curcumin induces mitochondrial apoptosis in human hepatoma cells through BCLAF1-mediated modulation of PI3K/AKT/GSK-3β signaling.
- Author
-
Bai, Chunhua, Zhao, Jiaqi, Su, Jielin, Chen, Jiaxin, Cui, Xinmu, Sun, Manqing, and Zhang, Xuewu
- Subjects
- *
CELL cycle , *CURCUMIN , *HEPATOCELLULAR carcinoma , *CHINESE medicine , *CELL anatomy , *MITOCHONDRIA - Abstract
Curcumin is a yellow pigment extracted from the rhizome of turmeric, a traditional Chinese medicine. Here, we tested the hypothesis that curcumin-mediated downregulation of BCLAF1 triggers mitochondrial apoptosis in hepatoma cells by inhibiting PI3K/AKT/GSK-3β signaling. Treatment of the human hepatoma cell lines, HepG2 and SK-Hep-1, with various concentrations of curcumin revealed a time-dependent and concentration-dependent inhibition of cell proliferation, increased apoptosis, cell cycle arrest at the G0/G1 phase, reduced mitochondrial membrane potential, and reduced expression levels of PI3K, p-PI3K, AKT, p-AKT, GSK-3β, and p-GSK-3β. Additionally, curcumin suppressed the levels of apoptotic factors after treating the cells with LY294002, a PI3K inhibitor. Curcumin also suppressed the expression of BCLAF1. Treating stable BCLAF1 knockout HepG2 and SK-Hep-1 cells with curcumin further enhanced apoptosis and increased the number of cells in G0/G1 cell cycle arrest, while inhibiting the downregulation of PI3K/AKT/GSK-3β pathway-related proteins. Treatment of a nude mouse xenograft model bearing HepG2 cells with curcumin inhibited tumor growth, disrupted the cellular structure of the tumor tissue, and suppressed the expression of BCLAF1 and PI3K/AKT/GSK-3β proteins. In summary, our in vitro and in vivo analyses show that curcumin downregulates BCLAF1 expression, inhibits the activation of the PI3K/AKT/GSK-3β pathway, and triggers mitochondrial apoptosis in HCC. These findings uncover a potential therapeutic strategy leveraging the antitumor effects of curcumin against HCC. [Display omitted] [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.